Valuation: Alumis Inc.

Market Cap 87Cr 78Cr 72Cr 65Cr 121.54Cr 8.27TCr 123.82Cr 855.77Cr 343.54Cr 4.35TCr 326.91Cr 319.96Cr 14TCr P/E 2026 *
-2.06x
P/E 2027 * -2.39x
Enterprise Value 16Cr 14Cr 13Cr 12Cr 22Cr 1.47TCr 22Cr 152.37Cr 61Cr 774.67Cr 58Cr 57Cr 2.44TCr EV / Sales 2026 *
24.8x
EV / Sales 2027 * 14.7x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.32%
1 week-0.74%
Current month-8.93%
1 month-8.93%
3 months-76.75%
6 months-72.74%
Current year-31.05%
1 week 6.3
Extreme 6.3
7.24
1 month 6.01
Extreme 6.01
7.31
Current year 6.01
Extreme 6.01
31.35
1 year 4.38
Extreme 4.385
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Director/Board Member 55 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26
Samsara BioCapital LLC
SellCompany -6,42,712 0.5207%
04/09/26 Other

Director

0 0%
03/08/26 Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
-2.32%-0.74%+44.42% - 87Cr
-0.62%-1.87%+46.31%+56.99% 6.38TCr
+0.35%+3.20%+14.92%+84.55% 5.64TCr
+0.53%+1.96%+15.37%+106.81% 5.46TCr
-2.81%-4.31%+23.50%+50.90% 4.41TCr
-0.33%-1.93%+20.15%+98.45% 4.21TCr
+0.55%+2.31%+224.97%+942.56% 4.1TCr
+3.27%+47.96%+112.67%+96.48% 3.49TCr
+1.22%-1.44%+14.89%+47.15% 3.28TCr
+0.89%+20.55%-42.03%+373.03% 2.47TCr
Average +0.07%+6.71%+47.52%+206.32% 3.95TCr
Weighted average by Cap. +0.17%+5.43%+48.49%+186.13%

Financials

2026 *2027 *
Net sales 62.61L 56.08L 51.58L 46.74L 87.36L 59Cr 89L 6.15Cr 2.47Cr 31Cr 2.35Cr 2.3Cr 99Cr 2.43Cr 2.18Cr 2Cr 1.82Cr 3.4Cr 231.06Cr 3.46Cr 24Cr 9.6Cr 121.54Cr 9.13Cr 8.94Cr 383.31Cr
Net income -43Cr -38Cr -35Cr -32Cr -60Cr -4.06TCr -61Cr -419.78Cr -168.52Cr -2.13TCr -160.36Cr -156.95Cr -6.73TCr -41Cr -37Cr -34Cr -31Cr -57Cr -3.88TCr -58Cr -401.46Cr -161.16Cr -2.04TCr -153.36Cr -150.1Cr -6.44TCr
Net Debt -72Cr -64Cr -59Cr -53Cr -100Cr -6.8TCr -101.77Cr -703.4Cr -282.37Cr -3.58TCr -268.71Cr -262.99Cr -11TCr -51Cr -46Cr -42Cr -38Cr -72Cr -4.88TCr -73Cr -504.86Cr -202.67Cr -2.57TCr -192.86Cr -188.76Cr -8.09TCr
Projected Income Statement - Annual - Alumis Inc.
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
30/26/30 $6.730 -2.32% 22,36,896
29/26/29 $6.890 -3.37% 27,43,467
28/26/28 $7.130 +7.38% 24,32,029
27/26/27 $6.640 +2.00% 32,61,304
26/26/26 $6.510 -3.98% 11,19,974
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Alumis Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.730USD
Average target price
31.12USD
Spread / Average Target
+362.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alumis Inc.
  1. Stock Market
  2. Stocks
  3. ALMS Stock